234.51 +0.01 (0.00%)
After hours: 4:08PM EST
|Bid||223.00 x 100|
|Ask||238.00 x 100|
|Day's Range||232.55 - 234.70|
|52 Week Range||169.19 - 234.70|
|PE Ratio (TTM)||50.98|
|Forward Dividend & Yield||3.00 (1.31%)|
|1y Target Est||N/A|
Becton, Dickinson's (BDX) focus in the Balloon-Angioplasty space is expected to lend the company a competitive edge in the niche MedTech markets.
The stock market’s relentless march upward has pushed the prices of many companies higher. Fortunately, Simply Safe Dividends identified 10 super-safe dividend growth stocks that investors can rely on for secure, fast-growing income. Let’s take a look at 10 of the safest dividend growth stocks in the market.
How Is Accelerate Diagnostics Positioned at the Start of 2018? In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock. As a result of the offering, the cash position of the company increased to $121.3 million at the end of 3Q17 as compared with $77.8 million at the end of 3Q16.
How Is Accelerate Diagnostics Positioned at the Start of 2018? The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17. For fiscal 2017, Accelerate Diagnostics is expected to report revenues of $5 million, while peers Becton Dickinson (BDX), Bruker (BRKR), and Thermo Fisher Scientific (TMO) are expected to report revenues of $12 billion, $1.7 billion, and $20.5 billion, respectively.
Tuscon-based Accelerate Diagnostics (AXDX) is a diagnostics company focused on developing solutions and tools to provide rapid diagnostic results. While results from traditional culture-based tests usually take two to three days, Accelerate’s technology platform is built to deliver substantially faster and more accurate testing of infectious pathogens. The platform is intended to rapidly diagnose infectious pathogens.
Stryker's 52-Week High: Should You Expect Further Upside?SYK stock at 52-week high On January 9, Stryker (SYK) traded at a 52-week high of $164.2 per share. The stock ended trading with a closing price of $160.4. As of January 9, 2018, SYK stock is trading higher than its 50-day moving average of $155 as well as the 200-day moving average of $148.1. Stryker traded at a 52-week low of $117.6 on January 9, 2017. The company’s one-year stock return is ~35% as of January 9, 2018.
Becton Dickinson and Co (NYSE: BDX ) was initiated with a top-notch rating by KeyBanc Capital Markets Thursday. The Analyst KeyBanc analyst Matthew Mishan initiated coverage on Becton Dickinson with an ...
Rating Action: Moody's downgrades Becton, Dickinson and Company to speculative grade. Global Credit Research- 28 Dec 2017. NOTE: On January 3, 2018, the press release was corrected as follows: In the first ...
When it comes to dividends, a large headline yield isn’t always the best choice. The reality is, stocks that grow those dividends consistently over time are actually better bets for portfolios. The combination of steadily higher dividends and capital appreciation from investors wanting those increases makes dividend growth stocks a potent choice for most portfolios.
Becton, Dickinson and Company (BDX), or BD, established itself as the leader in the medication management market with the acquisition of CareFusion in 2015.
With the recent technological advancements in healthcare, medical device players have faced cybersecurity risks time and again in recent years.
On December 28, Becton, Dickinson and Company (BDX), or BD, received clearance for its Bard (BCR) acquisition form MOFCOM (Ministry of Commerce of the People's Republic of China), but the approval is contingent ...